Experimental Drug Shows Promise in Glioblastoma Treatment
Men diagnosed with the most aggressive type of brain cancer, glioblastoma, are reportedly seeing no signs of the disease after undergoing treatment with an experimental drug.
Ben Trotman, who was 40 when he learned he had glioblastoma in 2022, faced a grim prognosis. Usually, patients with this condition live around 15 months post-diagnosis, with merely a 6.9% chance of surviving five years.
Trotman was treated at the Neurology and Neurosurgery Hospital at University College London (UCLH) by Dr. Paul Malholland, a consultant in medical oncology. The details of his case are outlined in a recent press release.
Potential Breakthrough with Immunotherapy
Trotman was the sole participant in a clinical trial that had to be closed due to a lack of patients. He received ipilimumab, a targeted immunotherapy designed to help the immune system fight cancer.
This antibody works by binding to proteins in T cells, which are crucial for immune response, preventing cancer cells from evading detection, according to the National Cancer Institute.
Along with this treatment, Trotman also underwent radiation and chemotherapy. Remarkably, more than two years later, his routine scans have indicated no signs of cancer.
“It’s quite unusual to have a clear scan with glioblastoma, especially since he didn’t undergo any follow-up procedures to remove the initial tumors,” Dr. Malholland noted.
“We felt we had a lucky break in an otherwise devastating situation.”
Dr. Malholland expressed hope that the combination of immunotherapy and further treatments will keep Trotman’s tumors from returning. Following his treatment, Trotman married his wife, Emily, just two months later, and they welcomed a daughter named Mabel in April 2025.
Emily reflected on their journey, saying, “Receiving this diagnosis was incredibly traumatic. It was hard to believe that Ben, who was clearly healthy, had this condition.” She added that finding Dr. Malholland was serendipitous, offering them a ray of hope amidst an overwhelming situation.
Ben acknowledged the uncertainty of the future but felt encouraged by the immunotherapy treatments and the clear scans. “It feels like a small glimmer of hope,” he said.
Both he and his wife are committed to rebuilding their lives, now focused on their new role as parents.
Dr. Malholland’s team has initiated another clinical trial for newly diagnosed glioblastoma patients. The new trial will see sixteen participants at UCLH’s clinical research facility and the National Hospital of Neurosurgery.
The approach involves administering ipilimumab before standard treatments like surgery, radiation, and chemotherapy are started.
In a related initiative, known as the “Margaret Trial,” funding was secured through the efforts of Dame Siobhain McDonagh. This trial is named in memory of her sister, who passed away from glioblastoma in 2023.
Ben expressed optimism regarding the new trials, emphasizing that the same immunotherapeutic drugs he received could potentially offer hope to others facing similar challenges.
